

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yamada A, Sasada T, Noguchi M, Itoh K	Next generation peptide vaccines for advanced cancer	Cancer Sci.	104(1)	15-21	2013
Noguchi M, Moriya F, Suekane S, Ohnishi R, Matsueda S, Sasada T, Yamada A, Itoh K.	A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: Prolongation of prostate-specific antigen doubling time.	BMC Cancer			2013
Takahashi R, Yoshitomi M, Yutani S, Shirahama T, Noguchi M, Yamada A, Itoh K, Sasada T.	Current status of immunotherapy for the treatment of biliary tract cancer.	Hum Vaccin Immunother.	9(5)		2013
Matsueda S, Komatsu N, Kusumoto K, Koga S, Yamada A, Kuromatsu R, Yamada S, Seki R, Yutani S, Shichijo S, Mine T, Fukuda T, Okamura T, Okuda S, Sata M, Honda J, Kaji M, Itoh K, Sasada T.	Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases.	Dev Comp Immunol	41(1)	68-76	2013
Yutani S, Komatsu N, Yoshitomi M, Matsueda S, Yonemoto K, Mine T, Noguchi M, Ishihara Y, Yamada A, Itoh K, Sasada T.	A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.	Oncol Rep.			2013

Takahashi R, Ishibashi Y, Hiraoka K, Matsueda S , Kawano K, Kawahara A, Kage M, Ohshima K, Yamanaka R, Shichijo S, Shirouzu K, Itoh K, Sasada T .	Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.	Cancer Sci			2013
Yutani S, Komatsu N, Matsueda S , Yoshitomi M, Shirahama T, Yamada A , Itoh K, Sasada T .	Juzentaihoto failed to augment antigen-specific immunity but prevented deterioration of patients' conditions in advanced pancreatic cancer under personalized peptide vaccine.	Evid Based Complement Alternat Med.			2013
Terasaki M, Murotani K, Narita Y, Nishikawa R, Sasada T, Yamada A, Itoh K, Morioka M.	Controversies in clinical trials of cancer vaccines for glioblastoma	J Vaccines Vaccines	4	171	2013